NRG
NVCR icon

Nemes Rush Group’s NovoCure NVCR Stock Holding History

Nemes Rush Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60
Closed -$1.07K – 724
2025
Q2 		$1.07K Hold
60
– – ﹤0.01% 649
2025
Q1 		$1.07K Hold
60
– – ﹤0.01% 648
2024
Q4 		$1.79K Hold
60
– – ﹤0.01% 626
2024
Q3 		$938 Hold
60
– – ﹤0.01% 551
2024
Q2 		$1.03K Hold
60
– – ﹤0.01% 554
2024
Q1 		$938 Hold
60
– – ﹤0.01% 609
2023
Q4 		$896 Hold
60
– – ﹤0.01% 607
2023
Q3 		$969 Hold
60
– – ﹤0.01% 587
2023
Q2 		$2.49K Buy
+60
New +$3.73K ﹤0.01% 546

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nemes Rush Group's NVCR Position: Q3 2025 in Review

Nemes Rush Group sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 60 shares — an estimated $1.07K sold.

Nemes Rush Group first reported a position in NVCR in Q2 2023 and held it in 9 quarters. The position peaked at $2.49K in Q2 2023. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Nemes Rush Group reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Nemes Rush Group sold 60 NovoCure shares in Q3 2025, an estimated $1.07K.
  • Nemes Rush Group first reported a position in NovoCure in Q2 2023 and held it in 9 quarters.
  • Nemes Rush Group's NovoCure position peaked at $2.49K in Q2 2023.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Nemes Rush Group's 13F filing for Q3 2025, filed 13 Nov 2025.